FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090085536> ?p ?o ?g. }

• W3090085536 endingPage "102543" @default.
• W3090085536 startingPage "102543" @default.
• W3090085536 abstract "Abstract Background Magnetic resonance imaging (MRI) data from multiple sclerosis (MS) patients treated in real-world settings are important for understanding disease-modifying therapy effects, including no evidence of disease activity (NEDA) assessment. This longitudinal, retrospective, single-cohort analysis assessed MRI and clinical disease outcomes in patients with relapsing-remitting MS treated with natalizumab for up to 5 years in Prague, the Czech Republic. Methods The primary study endpoint was the proportion of patients free of new or enlarging fluid-attenuated inversion recovery (FLAIR) lesions after at least 2 years of natalizumab treatment. Secondary endpoints included percentage brain volume change over time, the number of new T1-hypointense lesions that persisted for ≥6 months, FLAIR and T1-hypointense lesion volume change over time, and the proportion of patients with NEDA-3 (defined as no relapses, no confirmed disability worsening, and no new or enlarging FLAIR lesions). Results A total of 193 patients were included in the study. During year 1 of natalizumab treatment, 78.9% of patients had no new or enlarging FLAIR lesions and 79.5% had no new T1 lesions. These proportions increased in years 2–5, with ≥98.0% of patients free of new or enlarging FLAIR lesions and ≥98.8% free of new T1 lesions. During year 1 on natalizumab, 52.2% of patients achieved NEDA-3; this proportion increased to ≥69.2% in years 2–5. Conclusion This study provides additional evidence that long-term MS disease activity, as measured by both MRI activity and NEDA-3, is well-controlled in patients treated with natalizumab in real-world settings." @default.
• W3090085536 created "2020-10-08" @default.
• W3090085536 creator A5001679084 @default.
• W3090085536 creator A5008926112 @default.
• W3090085536 creator A5026528858 @default.
• W3090085536 creator A5028455166 @default.
• W3090085536 creator A5029839989 @default.
• W3090085536 creator A5064747903 @default.
• W3090085536 creator A5066502187 @default.
• W3090085536 creator A5071219650 @default.
• W3090085536 creator A5079965425 @default.
• W3090085536 creator A5082119673 @default.
• W3090085536 creator A5085322664 @default.
• W3090085536 date "2020-11-01" @default.
• W3090085536 modified "2023-10-17" @default.
• W3090085536 title "Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study" @default.
• W3090085536 cites W1988037885 @default.
• W3090085536 cites W2026913491 @default.
• W3090085536 cites W2103758700 @default.
• W3090085536 cites W2105053272 @default.
• W3090085536 cites W2105159132 @default.
• W3090085536 cites W2146662840 @default.
• W3090085536 cites W2164556363 @default.
• W3090085536 cites W2173315418 @default.
• W3090085536 cites W2239081917 @default.
• W3090085536 cites W2337612449 @default.
• W3090085536 cites W2481180990 @default.
• W3090085536 cites W2605302503 @default.
• W3090085536 cites W2611885830 @default.
• W3090085536 cites W266124145 @default.
• W3090085536 cites W2768711649 @default.
• W3090085536 cites W2769695548 @default.
• W3090085536 cites W2783703447 @default.
• W3090085536 cites W2810523187 @default.
• W3090085536 cites W4253381763 @default.
• W3090085536 cites W950990452 @default.
• W3090085536 doi "https://doi.org/10.1016/j.msard.2020.102543" @default.
• W3090085536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33296966" @default.
• W3090085536 hasPublicationYear "2020" @default.
• W3090085536 type Work @default.
• W3090085536 sameAs 3090085536 @default.
• W3090085536 citedByCount "11" @default.
• W3090085536 countsByYear W30900855362021 @default.
• W3090085536 countsByYear W30900855362022 @default.
• W3090085536 countsByYear W30900855362023 @default.
• W3090085536 crossrefType "journal-article" @default.
• W3090085536 hasAuthorship W3090085536A5001679084 @default.
• W3090085536 hasAuthorship W3090085536A5008926112 @default.
• W3090085536 hasAuthorship W3090085536A5026528858 @default.
• W3090085536 hasAuthorship W3090085536A5028455166 @default.
• W3090085536 hasAuthorship W3090085536A5029839989 @default.
• W3090085536 hasAuthorship W3090085536A5064747903 @default.
• W3090085536 hasAuthorship W3090085536A5066502187 @default.
• W3090085536 hasAuthorship W3090085536A5071219650 @default.
• W3090085536 hasAuthorship W3090085536A5079965425 @default.
• W3090085536 hasAuthorship W3090085536A5082119673 @default.
• W3090085536 hasAuthorship W3090085536A5085322664 @default.
• W3090085536 hasBestOaLocation W30900855361 @default.
• W3090085536 hasConcept C121332964 @default.
• W3090085536 hasConcept C126322002 @default.
• W3090085536 hasConcept C138885662 @default.
• W3090085536 hasConcept C167135981 @default.
• W3090085536 hasConcept C1862650 @default.
• W3090085536 hasConcept C187212893 @default.
• W3090085536 hasConcept C203014093 @default.
• W3090085536 hasConcept C2777842544 @default.
• W3090085536 hasConcept C2779134260 @default.
• W3090085536 hasConcept C2780640218 @default.
• W3090085536 hasConcept C2781004633 @default.
• W3090085536 hasConcept C3020694758 @default.
• W3090085536 hasConcept C41895202 @default.
• W3090085536 hasConcept C61797465 @default.
• W3090085536 hasConcept C62520636 @default.
• W3090085536 hasConcept C71924100 @default.
• W3090085536 hasConceptScore W3090085536C121332964 @default.
• W3090085536 hasConceptScore W3090085536C126322002 @default.
• W3090085536 hasConceptScore W3090085536C138885662 @default.
• W3090085536 hasConceptScore W3090085536C167135981 @default.
• W3090085536 hasConceptScore W3090085536C1862650 @default.
• W3090085536 hasConceptScore W3090085536C187212893 @default.
• W3090085536 hasConceptScore W3090085536C203014093 @default.
• W3090085536 hasConceptScore W3090085536C2777842544 @default.
• W3090085536 hasConceptScore W3090085536C2779134260 @default.
• W3090085536 hasConceptScore W3090085536C2780640218 @default.
• W3090085536 hasConceptScore W3090085536C2781004633 @default.
• W3090085536 hasConceptScore W3090085536C3020694758 @default.
• W3090085536 hasConceptScore W3090085536C41895202 @default.
• W3090085536 hasConceptScore W3090085536C61797465 @default.
• W3090085536 hasConceptScore W3090085536C62520636 @default.
• W3090085536 hasConceptScore W3090085536C71924100 @default.
• W3090085536 hasFunder F4320308604 @default.
• W3090085536 hasLocation W30900855361 @default.
• W3090085536 hasOpenAccess W3090085536 @default.
• W3090085536 hasPrimaryLocation W30900855361 @default.
• W3090085536 hasRelatedWork W2002890650 @default.
• W3090085536 hasRelatedWork W2151867003 @default.
• W3090085536 hasRelatedWork W2165393966 @default.
• W3090085536 hasRelatedWork W2343984847 @default.

• next